{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:52:02Z","timestamp":1793040722891,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ixchelsis Ltd"},{"name":"Samantha Abel"},{"name":"Ixchelsis Ltd"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"Abstract<\/jats:title>\n \n Introduction<\/jats:title>\n Few treatments are available for men with premature ejaculation (PE); oxytocin (OT) receptor antagonism in the central nervous system (CNS) is a potential new approach.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n To determine if cligosiban selectively inhibits human OT receptors, penetrates the CNS, shows pharmacology in the CNS, and effects ejaculatory physiology in pre-clinical systems.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Experiments complied with United Kingdom legislation and were subject to local ethical review. In\u00a0vitro potency and selectivity of cligosiban was assessed using recombinant and native OT receptor systems including both neuronal and non-neuronal cell types. Selectivity was determined over neighboring V1A, V1B, and V2 vasopressin receptors using a combination of recombinant and native vasopressin receptor assay systems. To determine an effect on central OT receptors and on ejaculation, cligosiban was evaluated in 2 anesthetized rat models\u2014the electromyography model of ejaculatory physiology and a model of OT-mediated CNS neuronal firing. The CNS penetration of cligosiban was also determined by measuring cerebrospinal fluid and plasma drug concentrations following an intravenous (IV) infusion in rats.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measure<\/jats:title>\n These were functional measures of pharmacology in\u00a0vitro, in cell lines and tissues, and in\u00a0vivo in rats.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Cligosiban is a potent OT receptor antagonist, with a base dissociation constant of 5.7 nmol\/L against native human uterine smooth muscle cell OT receptors. Cligosiban displays similar antagonistic potency against human recombinant and rat native OT receptors, including neuronal OT receptors. Cligosiban demonstrates &gt;100-fold selectivity over human V1A, V1B, and V2 vasopressin receptors. In the electromyography model, cligosiban (0.9 mg\/kg, IV bolus) reduced the bulbospongiosum burst pattern and contraction amplitude associated with ejaculation. In the anesthetized CNS neuronal firing model, the same dosing regimen of cligosiban (0.9 mg\/kg IV bolus) modulated the OT-mediated response in the nucleus tractus solitarius. After systemic dosing to rats, cligosiban showed good CNS penetration.<\/jats:p>\n <\/jats:sec>\n \n Clinical Implications<\/jats:title>\n As the first highly selective and centrally penetrant OT receptor antagonist, cligosiban represents a promising compound to test the clinical hypothesis that antagonism of central OT receptors may be of therapeutic benefit in the treatment of PE.<\/jats:p>\n <\/jats:sec>\n \n Strength & Limitations<\/jats:title>\n The pharmacology and selectivity of cligosiban is determined using functional assays in recombinant cell lines, native cell lines, and tissue. Functional outcomes in in\u00a0vivo systems are linked to CNS measures of pharmacology. The translation of the animal models of ejaculation to PE in man is unproven.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Cligosiban, a potent, selective OT receptor antagonist, demonstrated CNS penetration and pharmacology and, using the same dosing regimen, inhibited apomorphine-induced ejaculation in rats. Cligosiban is a promising compound to test the clinical hypothesis that antagonism of central OT receptors may be of therapeutic benefit in the treatment of PE.<\/jats:p>\n <\/jats:sec>","DOI":"10.1016\/j.jsxm.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T03:17:18Z","timestamp":1543893438000},"page":"1698-1706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cligosiban, A Novel Brain-Penetrant, Selective Oxytocin Receptor Antagonist, Inhibits Ejaculatory Physiology in Rodents"],"prefix":"10.1093","volume":"15","author":[{"given":"Chris","family":"Wayman","sequence":"first","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Russell","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Tang","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Weibly","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gaboardi","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Fisher","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Allers","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Jackson","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hawcock","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Wilson","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gupta","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Casey","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl R.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development \u00a0 , Sandwich , United Kingdom"},{"name":"Sexual Health Therapeutic Area \u00a0 , Sandwich , United Kingdom"},{"name":"Ixchelsis Ltd , Sandwich , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"2023012309333049700_bib1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"2023012309333049700_bib2","first-page":"41","article-title":"An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation","volume":"2","author":"Serefoglu","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"2023012309333049700_bib3","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1126\/science.1073885","article-title":"Identification of a potential ejaculation generator in the spinal cord","volume":"297","author":"Truitt","year":"2002","journal-title":"Science"},{"key":"2023012309333049700_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2008.03.043","article-title":"Ejaculation elicited by microstimulation of lumbar spinothalamic neurons","volume":"54","author":"Borgdorff","year":"2008","journal-title":"Eur Urol"},{"key":"2023012309333049700_bib5","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.2174\/13816128113199990333","article-title":"The control of male sexual response","volume":"19","author":"Courtois","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2023012309333049700_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.111.004952","article-title":"Pharmacology for the treatment of premature ejaculation","volume":"64","author":"Giuliano","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2023012309333049700_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: structure, function and regulation","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol Rev"},{"key":"2023012309333049700_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1210\/jcem-65-4-738","article-title":"Changes in oxytocin and vasopressin secretion during sexual activity in men","volume":"65","author":"Murphy","year":"1987","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"2023012309333049700_bib9","first-page":"1022","article-title":"Male anorgasmia treated with oxytocin","volume":"5","author":"Ishak","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"2023012309333049700_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0018-506X(85)90002-9","article-title":"Oxytocin improves male copulatory performance in rats","volume":"19","author":"Arletti","year":"1985","journal-title":"Horm Behav"},{"key":"2023012309333049700_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjp.2008.176","article-title":"Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anesthetized rats","volume":"154","author":"Cl\u00e9ment","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"Suppl. 2","key":"2023012309333049700_bib12","first-page":"11","article-title":"Oxytocin receptor gene deleted mice display disrupted sexual function\u2014increased ejaculatory latency in males, and abolishment of lordosis in females","volume":"6","author":"Wayman","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023012309333049700_bib13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/bph.12198","article-title":"Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action","volume":"169","author":"Clement","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2023012309333049700_bib14","first-page":"2506","article-title":"Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study","volume":"10","author":"Shinghal","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023012309333049700_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.bmcl.2009.11.097","article-title":"Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for\u00a0a biaryl substituent","volume":"20","author":"Brown","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2023012309333049700_bib16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1210\/endo-126-4-2095","article-title":"Oxytocin and vasopressin binding sites in the rat uterus: competition binding and inhibitory pA2 studies with oxytocin and oxytocin antagonists","volume":"126","author":"Chan","year":"1990","journal-title":"Endocrinology"},{"key":"2023012309333049700_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0304-3940(86)90554-9","article-title":"Motoneurone activity in an isolated spinal cord\u00a0preparation from the adult mouse","volume":"71","author":"Fulton","year":"1986","journal-title":"Neurosci Lett"},{"key":"2023012309333049700_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-9861(19980914)399:1<101::AID-CNE8>3.0.CO;2-5","article-title":"Oxytocinergic inputs to the nucleus of the solitary tract and dorsal motor nucleus of the vagus in neonatal rats","volume":"399","author":"Rinaman","year":"1998","journal-title":"J\u00a0Comp Neurol"},{"key":"2023012309333049700_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0301-0082(00)00064-2","article-title":"Vasopressin- and oxytocin-induced activity in the central nervous system: electrophysiological studies using in-vitro systems","volume":"64","author":"Raggenbass","year":"2001","journal-title":"Prog Neurobiol"},{"key":"2023012309333049700_bib20","first-page":"R155","article-title":"Release of vasopressin and oxytocin by paraventricular stimulation in rats","volume":"258","author":"Landgraf","year":"1990","journal-title":"Am J Physiol"},{"key":"2023012309333049700_bib21","author":"The CNS penetration was determined following a 2 mg\/kg IV bolus dose to rats and a subsequent 30 \u03bcg\/min\/kg infusion for 60 minutes. Unpublished data."},{"key":"2023012309333049700_bib22","first-page":"1547","article-title":"Pharmacokinetics, safety and tolerability of single oral doses of a novel oxytocin receptor antagonist cligosiban in development for premature ejaculation: three randomized clinical trials in healthy subjects","volume":"15","author":"Osterloh","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"2023012309333049700_bib23","first-page":"R441","article-title":"Intracavernous pressure during erection in rats: an integrative approach based on telemetric recording","volume":"276","author":"Bernabe","year":"1999","journal-title":"Am J Physiol"},{"key":"2023012309333049700_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neulet.2009.08.078","article-title":"Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection","volume":"465","author":"Richards","year":"2009","journal-title":"Neurosci Lett"},{"key":"2023012309333049700_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/bjp.2008.226","article-title":"Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V1A receptors and not oxytocin receptors","volume":"155","author":"Gupta","year":"2008","journal-title":"Br J Pharmacol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951831258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951831258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/15\/12\/1698\/48590215\/jsm_15_12_1698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/15\/12\/1698\/48590215\/jsm_15_12_1698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:57:10Z","timestamp":1674449830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/15\/12\/1698\/6980449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,1]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2018.10.008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734615130.793555095","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cligosiban, A Novel Brain-Penetrant, Selective Oxytocin Receptor Antagonist, Inhibits Ejaculatory Physiology in Rodents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}